Revenues

12 Months Ended

Dec. 31, 2023

Revenue from Contract with Customer [Abstract]

Revenues

Note 15. Revenues

The Company sells Sunosi and Auvelity in the United States through the Distributors. The Company sells Sunosi internationally through local distributors for delivery primarily to retail pharmacies and hospitals.

License revenue consists of the recognition of the upfront payment the Company received from Pharmanovia in February 2023, and royalty revenue is related to sales of Sunosi by Pharmanovia in certain ex-U.S. markets.

The following table presents a summary of total revenues by product:

By Product

	Year ended December 31,
	2023		2022
Product sales, net
Auvelity	$	130,072	$	5,168
Sunosi		72,388		44,869
Total product sales, net		202,460		50,037
Sunosi license revenue		65,735		—
Sunosi royalty revenue		2,405		—
Total revenues	$	270,600	$	50,037

The following table presents a summary of total revenues by geographic location:

By Geographic Location

	Year ended December 31,
	2023		2022
Product sales, net
United States	$	197,224	$	49,132
Outside of the United States		5,236		905
Total product sales, net		202,460		50,037
License revenue
Outside of the United States		65,735		—
Royalty revenue
Outside of the United States		2,405		—
Total revenues	$	270,600	$	50,037

For the year ended December 31, 2023, product sales, net includes adjustments for provisions for product sales made in 2022 resulting from changes in estimates of $0.1 million for Sunosi and $0.8 million for Auvelity.